Cefiderocol Activity Against Carbapenem-Resistant Gram-Negative Bacteria: Insights from a European Surveillance Study

Study Background and Research Question

Carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter spp. are among the most formidable threats in clinical microbiology, as recognized by the World Health Organization. Treatment options for these non-fermenting Gram-negative pathogens are limited, particularly as resistance to standard β-lactam/β-lactamase inhibitor combinations continues to rise. The referenced study (Santerre Henriksen et al., 2024) sought to systematically profile the in vitro susceptibility of European clinical isolates—focusing on both carbapenem-resistant and multidrug-resistant phenotypes—against cefiderocol, a novel siderophore cephalosporin, in direct comparison with recent β-lactam/β-lactamase inhibitor regimens.

Key Innovation from the Reference Study

This investigation is notable for its scale and its side-by-side analysis of cefiderocol with both established and investigational β-lactam/β-lactamase inhibitor combinations. Critically, it is the first to directly benchmark cefiderocol against non-licensed inhibitor regimens in a pan-European context and to dissect resistance mechanisms using advanced molecular methods in resistant isolates. The study’s design ensures that observed antibiotic activity accurately reflects clinical resistance breakpoints, especially for high-dose meropenem, thereby maximizing translational relevance for therapeutic decision-making (Santerre Henriksen et al., 2024).

Methods and Experimental Design Insights

Researchers collected 1,451 non-fermenting Gram-negative isolates (950 P. aeruginosa, 501 Acinetobacter spp.) from 49 sites across six European countries over a one-year period. Susceptibility testing encompassed cefiderocol and multiple β-lactam/β-lactamase inhibitor combinations, including both licensed and investigational agents. Meropenem-resistant isolates (MIC >8 mg/L) underwent targeted PCR for β-lactamase gene detection, while cefiderocol-resistant isolates were subjected to whole-genome sequencing to identify resistance determinants and relevant mutations.

To ensure clinical relevance, meropenem resistance was defined using breakpoints appropriate for high-dose regimens. This approach allowed the study to capture resistance phenotypes that would persist under real-world treatment conditions. The breadth of both phenotypic and genotypic data provides a robust foundation for interpreting emerging resistance mechanisms.

Core Findings and Why They Matter

Cefiderocol demonstrated high in vitro activity against both P. aeruginosa and Acinetobacter spp., substantially outperforming β-lactam/β-lactamase inhibitor combinations, especially in multidrug-resistant subsets. Among P. aeruginosa isolates, overall cefiderocol susceptibility was 98.9%, compared to 83.3%–91.4% for other inhibitors. For meropenem-resistant P. aeruginosa, the difference was even more pronounced: 97.8% cefiderocol susceptibility versus 12.2%–59.7% for comparators. Notably, cefiderocol retained activity against isolates resistant to both meropenem and ceftazidime-avibactam (96.7% susceptible) or ceftolozane-tazobactam (98.4% susceptible), underscoring its unique profile.

Acinetobacter spp. showed similarly encouraging results, with cefiderocol and sulbactam-durlobactam exhibiting the highest susceptibilities (92.4% and 97.0%, respectively). Even among meropenem-resistant Acinetobacter (n=227), cefiderocol maintained an 85.0% susceptibility rate. However, susceptibility dropped sharply (to 65.8%) among cefiderocol-resistant Acinetobacter, highlighting the ongoing risk of emergent resistance.

Molecular analysis revealed that meropenem-resistant P. aeruginosa primarily harbored metallo-β-lactamases (notably bla_VIM-2), while Acinetobacter spp. frequently carried oxacillinases (bla_OXA-23). In cefiderocol-resistant isolates, acquired β-lactamase genes and mutations in siderophore receptor genes (pirA-like or piuA) were common, suggesting multifactorial resistance pathways (Santerre Henriksen et al., 2024).

These findings are clinically significant: cefiderocol’s robust activity, even in the face of resistance to other advanced regimens, provides critical evidence supporting its use where few alternatives exist. Furthermore, the genetic insights highlight targets for ongoing surveillance and resistance mitigation.

Comparison with Existing Internal Articles

Recent internal literature, such as "Aztreonam’s Mechanistic Insights: Beyond Gram-Negative Targeting" and "Aztreonam: Monocyclic β-Lactam Antibiotic for Resistance Assays", underscores the role of monocyclic β-lactam antibiotics in resistance modeling and assay development. Aztreonam, in particular, offers targeted inhibition of Gram-negative aerobic bacteria and serves as a benchmark for multidrug resistance research. While the reference study centers on cefiderocol, both agents share the overarching mechanism of inhibition of bacterial cell wall synthesis, though cefiderocol’s siderophore-mediated uptake distinguishes its activity spectrum.

These internal resources detail Aztreonam’s additional effects, such as bone marrow progenitor cell inhibition and modulation of hepatic cytochrome P450 enzymes, which are not the primary focus of cefiderocol but represent important considerations in comprehensive resistance assay design. Together, these works establish a framework for integrating new antibiotics like cefiderocol and established agents like Aztreonam in advanced Gram-negative resistance modeling and phenotypic testing workflows.

Limitations and Transferability

Despite its strengths, the reference study is limited by its in vitro design; clinical efficacy and pharmacodynamic factors were not directly assessed. The geographic focus on Europe, while valuable for regional surveillance, may not fully capture resistance dynamics in other settings. Additionally, the observed drop in cefiderocol susceptibility among isolates already resistant to sulbactam-durlobactam or cefiderocol itself highlights the ongoing need for vigilance and alternative strategies.

Transferability to clinical practice hinges on rapid, parallel susceptibility testing—a key recommendation from the study. Early identification of cefiderocol-susceptible isolates could meaningfully expand the therapeutic arsenal against non-fermenting Gram-negative infections, especially in settings with high carbapenem resistance.

Protocol Parameters

• Isolate collection: Hospitalized inpatients; respiratory tract specimens were predominant (42% for P. aeruginosa, 39.3% for Acinetobacter spp.).
• Susceptibility testing: Performed for cefiderocol and multiple β-lactam/β-lactamase inhibitor combinations, using EUCAST/CLSI methods.
• Carbapenem resistance definition: MIC >8 mg/L for meropenem to reflect high-dose clinical breakpoints.
• Genotypic analysis: PCR for β-lactamase gene detection; whole-genome sequencing for cefiderocol-resistant isolates to identify acquired resistance mechanisms and receptor mutations.
• Recommended workflow: Early, parallel susceptibility testing of cefiderocol and comparator antibiotics in clinical isolates suspected of multidrug resistance.

Research Support Resources

For researchers developing or benchmarking resistance assays, Aztreonam (SKU A5931, APExBIO) remains a robust, well-characterized monocyclic β-lactam antibiotic for selective targeting and modeling of Gram-negative aerobic bacteria. Its well-documented inhibition of bacterial cell wall synthesis, along with effects on bone marrow progenitor cells and liver cytochrome P450 enzymes, enables multifaceted assay design and interpretation. Aztreonam’s high solubility in water and DMSO, as well as its stability profile, support flexible laboratory workflows. For advanced resistance modeling or as a comparator agent, Aztreonam can be integrated alongside newer molecules such as cefiderocol to inform next-generation antimicrobial research.